- Page 1 and 2: Annual Update in Intensive Care and
- Page 3 and 4: The series Annual Update in Intensi
- Page 5 and 6: VI Table of Contents IV Endotrachea
- Page 7 and 8: VIII Table of Contents XI Periopera
- Page 9 and 10: List of Contributors Abroug F Inten
- Page 11 and 12: Cecconi M Department of General Int
- Page 13: Garcia X Department of Critical Car
- Page 17 and 18: Murias G Intensive Care Unit Clinic
- Page 19 and 20: Reuter DA Department of Anesthesiol
- Page 21 and 22: Sobol J Department of Anesthesiolog
- Page 23 and 24: Wunsch H Department of Anesthesiolo
- Page 25 and 26: Section I 1 I Mechanisms of Sepsis
- Page 27 and 28: 4 M.A.D. van Zoelen, A. Achouiti, a
- Page 29 and 30: 6 M.A.D. van Zoelen, A. Achouiti, a
- Page 31 and 32: 8 M.A.D. van Zoelen, A. Achouiti, a
- Page 33 and 34: 10 M.A.D. van Zoelen, A. Achouiti,
- Page 35 and 36: 12 M.A.D. van Zoelen, A. Achouiti,
- Page 37 and 38: 14 M.A.D. van Zoelen, A. Achouiti,
- Page 39 and 40: 16 I The Endocannabinoid System: A
- Page 41 and 42: 18 C. Lehmann, V. Cerny, and M. Mat
- Page 43 and 44: 20 C. Lehmann, V. Cerny, and M. Mat
- Page 45 and 46: 22 C. Lehmann, V. Cerny, and M. Mat
- Page 47 and 48: 24 C. Lehmann, V. Cerny, and M. Mat
- Page 49 and 50: 26 I Remote Ischemic Conditioning a
- Page 51 and 52: 28 P. Meybohm and B. Bein I Remote
- Page 53 and 54: 30 P. Meybohm and B. Bein I other i
- Page 55 and 56: 32 P. Meybohm and B. Bein I determi
- Page 57 and 58: 34 P. Meybohm and B. Bein I to enco
- Page 59 and 60: 36 P. Meybohm and B. Bein I 39. Wal
- Page 61 and 62: 38 S.N. Heyman, S. Rosen, and C. Ro
- Page 63 and 64: 40 S.N. Heyman, S. Rosen, and C. Ro
- Page 65 and 66:
42 S.N. Heyman, S. Rosen, and C. Ro
- Page 67 and 68:
44 S.N. Heyman, S. Rosen, and C. Ro
- Page 69 and 70:
46 S.N. Heyman, S. Rosen, and C. Ro
- Page 71 and 72:
Section II 49 II Coagulation System
- Page 73 and 74:
52 X. Delabranche, F. Toti, and F.
- Page 75 and 76:
54 X. Delabranche, F. Toti, and F.
- Page 77 and 78:
56 X. Delabranche, F. Toti, and F.
- Page 79 and 80:
58 X. Delabranche, F. Toti, and F.
- Page 81 and 82:
60 X. Delabranche, F. Toti, and F.
- Page 83 and 84:
62 II The Inflammatory Potential of
- Page 85 and 86:
64 C. Jennewein, N. Tran, and K. Za
- Page 87 and 88:
66 C. Jennewein, N. Tran, and K. Za
- Page 89 and 90:
68 C. Jennewein, N. Tran, and K. Za
- Page 91 and 92:
70 II Iron Deficiency in Critically
- Page 93 and 94:
72 N.Heming,P.Montravers,andS.Lasoc
- Page 95 and 96:
74 N.Heming,P.Montravers,andS.Lasoc
- Page 97 and 98:
76 N.Heming,P.Montravers,andS.Lasoc
- Page 99 and 100:
78 N.Heming,P.Montravers,andS.Lasoc
- Page 101 and 102:
80 II Heparin-induced Thrombocytope
- Page 103 and 104:
82 Y. Sakr II increase the risk of
- Page 105 and 106:
84 Y. Sakr II Thrombotic Complicati
- Page 107 and 108:
86 Y. Sakr II used. The agglutinati
- Page 109 and 110:
88 Y. Sakr II In30%ofpatientswhoare
- Page 111 and 112:
90 Y. Sakr II The Challenge of Diag
- Page 113 and 114:
92 Y. Sakr II tures of heparin-indu
- Page 115 and 116:
Section III 95 III Acute Respirator
- Page 117 and 118:
98 N.J. Meyer and J.D. Christie III
- Page 119 and 120:
100 N.J. Meyer and J.D. Christie II
- Page 121 and 122:
102 N.J. Meyer and J.D. Christie II
- Page 123 and 124:
104 N.J. Meyer and J.D. Christie II
- Page 125 and 126:
106 N.J. Meyer and J.D. Christie II
- Page 127 and 128:
108 N.J. Meyer and J.D. Christie II
- Page 129 and 130:
110 F. Dachraoui, L. Ouanes-Besbes,
- Page 131 and 132:
112 F. Dachraoui, L. Ouanes-Besbes,
- Page 133 and 134:
114 F. Dachraoui, L. Ouanes-Besbes,
- Page 135 and 136:
116 F. Dachraoui, L. Ouanes-Besbes,
- Page 137 and 138:
118 I. Galvin and N.D. Ferguson III
- Page 139 and 140:
120 I. Galvin and N.D. Ferguson III
- Page 141 and 142:
122 I. Galvin and N.D. Ferguson III
- Page 143 and 144:
124 I. Galvin and N.D. Ferguson III
- Page 145 and 146:
126 I. Galvin and N.D. Ferguson III
- Page 147 and 148:
128 I. Galvin and N.D. Ferguson III
- Page 149 and 150:
Rapid Sequence Intubation: Overview
- Page 151 and 152:
Pre-hospital Rapid Sequence Intubat
- Page 153 and 154:
ecommend its use in the setting of
- Page 155 and 156:
Table 1. Hypnotic agents Agent Dose
- Page 157 and 158:
Rapid Sequence Intubation: Overview
- Page 159 and 160:
Conclusion Rapid sequence intubatio
- Page 161 and 162:
Rapid Sequence Intubation: Overview
- Page 163 and 164:
Alterations in Oral Microbial Ecolo
- Page 165 and 166:
pharynx is deemed to play an import
- Page 167 and 168:
Table 1. The BRUSHED Assessment Mod
- Page 169 and 170:
Research Priorities in Oral Care fo
- Page 171 and 172:
Conclusion Research Priorities in O
- Page 173 and 174:
Research Priorities in Oral Care fo
- Page 175 and 176:
Pros and Cons of Assisted Mechanica
- Page 177 and 178:
Pros and Cons of Assisted Mechanica
- Page 179 and 180:
NoisyPSVhasanadvantageoverotherassi
- Page 181 and 182:
Pros and Cons of Assisted Mechanica
- Page 183 and 184:
improvement in lung elastance, with
- Page 185 and 186:
controlled mechanical ventilation [
- Page 187 and 188:
References Pros and Cons of Assiste
- Page 189 and 190:
Pros and Cons of Assisted Mechanica
- Page 191 and 192:
Can ’Permissive’ Hypercapnia Mo
- Page 193 and 194:
Can ’Permissive’ Hypercapnia Mo
- Page 195 and 196:
Can ’Permissive’ Hypercapnia Mo
- Page 197 and 198:
Can ’Permissive’ Hypercapnia Mo
- Page 199 and 200:
Can ’Permissive’ Hypercapnia Mo
- Page 201 and 202:
However, concerns persist, particul
- Page 203 and 204:
Can ’Permissive’ Hypercapnia Mo
- Page 205 and 206:
NAVA: Why, When, Who? 189 Restricte
- Page 207 and 208:
Table 1. Summary of recent human ph
- Page 209 and 210:
Essentially, neural (EAdi) monitori
- Page 211 and 212:
NAVA: Why, When, Who? 195 16. Girar
- Page 213 and 214:
Therapeutic Aerosols in Mechanicall
- Page 215 and 216:
a) Jet nebulizer b) Ultrasonic nebu
- Page 217 and 218:
Therapeutic Aerosols in Mechanicall
- Page 219 and 220:
Therapeutic Aerosols in Mechanicall
- Page 221 and 222:
References Therapeutic Aerosols in
- Page 223 and 224:
Section VI 207 VI Cardiac Crises VI
- Page 225 and 226:
210 S. Scolletta, B. Biagioli, and
- Page 227 and 228:
212 S. Scolletta, B. Biagioli, and
- Page 229 and 230:
214 S. Scolletta, B. Biagioli, and
- Page 231 and 232:
216 S. Scolletta, B. Biagioli, and
- Page 233 and 234:
218 S. Scolletta, B. Biagioli, and
- Page 235 and 236:
220 VI Evolving Rationale for Minim
- Page 237 and 238:
222 J.G. Wigginton, A.H. Idris, and
- Page 239 and 240:
224 J.G. Wigginton, A.H. Idris, and
- Page 241 and 242:
226 J.G. Wigginton, A.H. Idris, and
- Page 243 and 244:
228 J.G. Wigginton, A.H. Idris, and
- Page 245 and 246:
230 J.G. Wigginton, A.H. Idris, and
- Page 247 and 248:
Hypoalbuminemia as a Risk Factor fo
- Page 249 and 250:
Microcirculation Possibly, at least
- Page 251 and 252:
Hypoalbuminemia as a Risk Factor fo
- Page 253 and 254:
Hypoalbuminemia as a Risk Factor fo
- Page 255 and 256:
Hypoalbuminemia as a Risk Factor fo
- Page 257 and 258:
Tubular Function Tubular concentrat
- Page 259 and 260:
injury, failure, need for renal rep
- Page 261 and 262:
Developing Biological Markers 247 a
- Page 263 and 264:
Conclusion The discovery of several
- Page 265 and 266:
Biomarkers of Acute Kidney Injury i
- Page 267 and 268:
and acute tubular necrosis is unpro
- Page 269 and 270:
utility (Breathing Not Properly stu
- Page 271 and 272:
NGAL, in various other complexes wi
- Page 273 and 274:
tantly, a positive association with
- Page 275 and 276:
References Biomarkers of Acute Kidn
- Page 277 and 278:
Cardio-renal Syndromes: A Complex S
- Page 279 and 280:
����� Cardio-renal Syndro
- Page 281 and 282:
Cardio-renal Syndromes: A Complex S
- Page 283 and 284:
Cardio-renal Syndromes: A Complex S
- Page 285 and 286:
Cardio-renal Syndromes: A Complex S
- Page 287 and 288:
Blood Purification in Sepsis and Ac
- Page 289 and 290:
Blood Purification in Sepsis and Ac
- Page 291 and 292:
Blood Purification in Sepsis and Ac
- Page 293 and 294:
Blood Purification in Sepsis and Ac
- Page 295 and 296:
Blood Purification in Sepsis and Ac
- Page 297 and 298:
Blood Purification in Sepsis and Ac
- Page 299 and 300:
The Lymphatic Vasculature as a Part
- Page 301 and 302:
FormationofLymph The Lymphatic Vasc
- Page 303 and 304:
The Lymphatic Vasculature as a Part
- Page 305 and 306:
The Lymphatic Vasculature as a Part
- Page 307 and 308:
The Lymphatic Vasculature as a Part
- Page 309 and 310:
The Interstitium and Lymphatics hav
- Page 311 and 312:
The Interstitium and Lymphatics hav
- Page 313 and 314:
The Interstitium and Lymphatics hav
- Page 315 and 316:
The Interstitium and Lymphatics hav
- Page 317 and 318:
The Interstitium and Lymphatics hav
- Page 319 and 320:
Fluid is a Drug that can be Overdos
- Page 321 and 322:
Table 1. Fluid overload and outcome
- Page 323 and 324:
Conclusion The studies discussed ab
- Page 325 and 326:
Crystalloid or Colloid Fluids: A Ma
- Page 327 and 328:
More Saline than Colloid Needed? Cr
- Page 329 and 330:
Crystalloid or Colloid Fluids: A Ma
- Page 331 and 332:
Crystalloid or Colloid Fluids: A Ma
- Page 333 and 334:
Crystalloid or Colloid Fluids: A Ma
- Page 335 and 336:
The Cyclic Effects of Mechanical Ve
- Page 337 and 338:
PracticalUseofPPVinPatientswithARDS
- Page 339 and 340:
Meaning of Pulse Pressure Variation
- Page 341 and 342:
References Meaning of Pulse Pressur
- Page 343 and 344:
Meaning of Pulse Pressure Variation
- Page 345 and 346:
however, an overall assessment of t
- Page 347 and 348:
Fig. 2. Varying response to stoke v
- Page 349 and 350:
Table 1. An example of a safety pro
- Page 351 and 352:
References The Fluid Challenge 339
- Page 353 and 354:
Facing the Challenge: A Rational St
- Page 355 and 356:
Facing the Challenge: A Rational St
- Page 357 and 358:
Facing the Challenge: A Rational St
- Page 359 and 360:
Facing the Challenge: A Rational St
- Page 361 and 362:
Facing the Challenge: A Rational St
- Page 363 and 364:
Facing the Challenge: A Rational St
- Page 365 and 366:
Section IX 353 IX The Microcirculat
- Page 367 and 368:
356 M.A. Puskarich and A.E. Jones I
- Page 369 and 370:
358 M.A. Puskarich and A.E. Jones I
- Page 371 and 372:
360 M.A. Puskarich and A.E. Jones I
- Page 373 and 374:
362 M.A. Puskarich and A.E. Jones I
- Page 375 and 376:
364 M.A. Puskarich and A.E. Jones I
- Page 377 and 378:
366 IX How Can We Use Tissue Carbon
- Page 379 and 380:
368 E. Futier, J.-L. Teboul, and B.
- Page 381 and 382:
370 E. Futier, J.-L. Teboul, and B.
- Page 383 and 384:
372 E. Futier, J.-L. Teboul, and B.
- Page 385 and 386:
374 E. Futier, J.-L. Teboul, and B.
- Page 387 and 388:
376 X.Garcia,F.X.Guyette,andM.R.Pin
- Page 389 and 390:
378 X.Garcia,F.X.Guyette,andM.R.Pin
- Page 391 and 392:
380 IX The Microcirculation of the
- Page 393 and 394:
382 A.P.C. Top, R.C. Tasker, and C.
- Page 395 and 396:
384 A.P.C.Top,R.C.Tasker,andC.Ince
- Page 397 and 398:
386 A.P.C. Top, R.C. Tasker, and C.
- Page 399 and 400:
388 A.P.C. Top, R.C. Tasker, and C.
- Page 401 and 402:
390 A.P.C. Top, R.C. Tasker, and C.
- Page 403 and 404:
Heart Rate as Prognostic Marker and
- Page 405 and 406:
Heart Rate as Prognostic Marker and
- Page 407 and 408:
Fig. 3. Effects of baseline heart r
- Page 409 and 410:
Heart Rate as Prognostic Marker and
- Page 411 and 412:
heart rate 140 120 100 80 60 40 20
- Page 413 and 414:
Heart Rate as Prognostic Marker and
- Page 415 and 416:
Heart Rate as Prognostic Marker and
- Page 417 and 418:
in conjunction with cardiogenic sho
- Page 419 and 420:
Table 1. Summary of different hemod
- Page 421 and 422:
Hemodynamic Monitoring in Cardiogen
- Page 423 and 424:
variations of the left sided time-v
- Page 425 and 426:
Hemodynamic Monitoring in Cardiogen
- Page 427 and 428:
Hemodynamic Monitoring in Cardiogen
- Page 429 and 430:
Non-Invasive Estimation of Left Ven
- Page 431 and 432:
Non-Invasive Estimation of Left Ven
- Page 433 and 434:
Non-Invasive Estimation of Left Ven
- Page 435 and 436:
Fig. 1. Original theory by Otto Fra
- Page 437 and 438:
Hemodynamics from the Periphery 427
- Page 439 and 440:
Hemodynamics from the Periphery 429
- Page 441 and 442:
Hemodynamics from the Periphery 431
- Page 443 and 444:
Hemodynamics from the Periphery 433
- Page 445 and 446:
Totally Non-invasive Continuous Car
- Page 447 and 448:
Totally Non-invasive Continuous Car
- Page 449 and 450:
Totally Non-invasive Continuous Car
- Page 451 and 452:
There are some limitations to the u
- Page 453 and 454:
Cardiac Output Monitoring: An Integ
- Page 455 and 456:
Cardiac Output Monitoring: An Integ
- Page 457 and 458:
Cardiac Output Monitoring: An Integ
- Page 459 and 460:
occurring signal variation with dif
- Page 461 and 462:
Table 2. (continued) Additional var
- Page 463 and 464:
Fig. 2. Integrative concept for the
- Page 465 and 466:
Cardiac Output Monitoring: An Integ
- Page 467 and 468:
Section XI 457 XI Perioperative Med
- Page 469 and 470:
460 N. Brienza, L. Dalfino, and M.T
- Page 471 and 472:
462 N. Brienza, L. Dalfino, and M.T
- Page 473 and 474:
464 N. Brienza, L. Dalfino, and M.T
- Page 475 and 476:
466 N. Brienza, L. Dalfino, and M.T
- Page 477 and 478:
468 N. Brienza, L. Dalfino, and M.T
- Page 479 and 480:
470 N. Brienza, L. Dalfino, and M.T
- Page 481 and 482:
472 S.G. De Hert and P.F. Wouters X
- Page 483 and 484:
474 S.G. De Hert and P.F. Wouters X
- Page 485 and 486:
476 S.G. De Hert and P.F. Wouters X
- Page 487 and 488:
478 S.G. De Hert and P.F. Wouters X
- Page 489 and 490:
A New Approach to Ventilator-associ
- Page 491 and 492:
Underlying Diseases A New Approach
- Page 493 and 494:
A New Approach to Ventilator-associ
- Page 495 and 496:
A New Approach to Ventilator-associ
- Page 497 and 498:
organisms in acute respiratory infe
- Page 499 and 500:
A New Approach to Ventilator-associ
- Page 501 and 502:
Selective Decontamination of the Di
- Page 503 and 504:
SDD/SOD and Antibiotic Resistance A
- Page 505 and 506:
study the effects of SDD and SOD on
- Page 507 and 508:
Selective Decontamination of the Di
- Page 509 and 510:
New Treatment Options against Gram-
- Page 511 and 512:
Table 1. Classification schemes for
- Page 513 and 514:
are currently no antibacterials in
- Page 515 and 516:
activity of BAL 30376 against vario
- Page 517 and 518:
New Treatment Options against Gram-
- Page 519 and 520:
Panipenem/betamipron New Treatment
- Page 521 and 522:
References New Treatment Options ag
- Page 523 and 524:
New Treatment Options against Gram-
- Page 525 and 526:
The ‘Bug’ In order to ensure ou
- Page 527 and 528:
tum [38].Allthreecompoundsarefungic
- Page 529 and 530:
Antifungal Therapy in The ICU: The
- Page 531 and 532:
Antifungal Therapy in The ICU: The
- Page 533 and 534:
Renal Dysfunction Antifungal Therap
- Page 535 and 536:
For fusariosis, voriconazole, posac
- Page 537 and 538:
Antifungal Therapy in The ICU: The
- Page 539 and 540:
Mycobacterial Sepsis and Multiorgan
- Page 541 and 542:
Other Systems Seeding of every orga
- Page 543 and 544:
Mycobacterial Sepsis and Multiorgan
- Page 545 and 546:
mediuminthepresenceandabsenceofanti
- Page 547 and 548:
Table 1. Suggested treatment regime
- Page 549 and 550:
Mycobacterial Sepsis and Multiorgan
- Page 551 and 552:
Pentraxin 3 (PTX3): Possible Role i
- Page 553 and 554:
patients, anti-PTX3 antibodies are
- Page 555 and 556:
Fig. 2. Pentraxin 3 (PTX3) in septi
- Page 557 and 558:
Pentraxin3(PTX3):PossibleRoleinCrit
- Page 559 and 560:
The Role of IgM- and IgA-enriched I
- Page 561 and 562:
The Role of IgM- and IgA-enriched I
- Page 563 and 564:
The Role of IgM- and IgA-enriched I
- Page 565 and 566:
Spontaneous Bacterial Peritonitis i
- Page 567 and 568:
of the splanchnic sympathetic nervo
- Page 569 and 570:
concomitant malignancy or traumatic
- Page 571 and 572:
These criteria seem to be very sens
- Page 573 and 574:
Spontaneous Bacterial Peritonitis i
- Page 575 and 576:
Prognosis When SBP was initially de
- Page 577 and 578:
significant effect on the probabili
- Page 579 and 580:
Spontaneous Bacterial Peritonitis i
- Page 581 and 582:
Spontaneous Bacterial Peritonitis i
- Page 583 and 584:
Fig. 1. The ‘critical mass’ con
- Page 585 and 586:
Acute-on-chronic Liver Failure: An
- Page 587 and 588:
Acute-on-chronic Liver Failure: An
- Page 589 and 590:
Fig. 4. Representative scheme of th
- Page 591 and 592:
Survival benefit with MARS in patie
- Page 593 and 594:
Acute-on-chronic Liver Failure: An
- Page 595 and 596:
Section XIV 589 XIV Trauma and Emer
- Page 597 and 598:
XIV 592 J.E. Hollander and A.M. Cha
- Page 599 and 600:
XIV 594 J.E. Hollander and A.M. Cha
- Page 601 and 602:
XIV 596 J.E. Hollander and A.M. Cha
- Page 603 and 604:
XIV 598 J.E. Hollander and A.M. Cha
- Page 605 and 606:
XIV 600 C. Hommers and J. Nolan sys
- Page 607 and 608:
XIV 602 C. Hommers and J. Nolan 97-
- Page 609 and 610:
XIV 604 C. Hommers and J. Nolan exp
- Page 611 and 612:
XIV 606 C. Hommers and J. Nolan per
- Page 613 and 614:
XIV 608 C. Hommers and J. Nolan 4.
- Page 615 and 616:
XIV 610 C. Hommers and J. Nolan 49.
- Page 617 and 618:
XIV 612 H. Schoechl, W. Voelckel, a
- Page 619 and 620:
XIV 614 H. Schoechl, W. Voelckel, a
- Page 621 and 622:
XIV 616 H. Schoechl, W. Voelckel, a
- Page 623 and 624:
XIV 618 H. Schoechl, W. Voelckel, a
- Page 625 and 626:
XIV 620 H.Schoechl,W.Voelckel,andC.
- Page 627 and 628:
XIV 622 H. Schoechl, W. Voelckel, a
- Page 629 and 630:
XIV 624 H. Schoechl, W. Voelckel, a
- Page 631 and 632:
XIV 626 H. Schoechl, W. Voelckel, a
- Page 633 and 634:
Section XV 629 XV Neurological Aspe
- Page 635 and 636:
632 S. Legriel, F. Pico, and E. Azo
- Page 637 and 638:
634 S. Legriel, F. Pico, and E. Azo
- Page 639 and 640:
636 S. Legriel, F. Pico, and E. Azo
- Page 641 and 642:
638 S. Legriel, F. Pico, and E. Azo
- Page 643 and 644:
640 S. Legriel, F. Pico, and E. Azo
- Page 645 and 646:
642 S. Legriel, F. Pico, and E. Azo
- Page 647 and 648:
644 S. Legriel, F. Pico, and E. Azo
- Page 649 and 650:
646 S. Legriel, F. Pico, and E. Azo
- Page 651 and 652:
648 S. Legriel, F. Pico, and E. Azo
- Page 653 and 654:
650 S. Legriel, F. Pico, and E. Azo
- Page 655 and 656:
652 S. Legriel, F. Pico, and E. Azo
- Page 657 and 658:
654 XV Prediction of Neurological O
- Page 659 and 660:
656 C. Sandroni, F. Cavallaro, and
- Page 661 and 662:
658 C. Sandroni, F. Cavallaro, and
- Page 663 and 664:
660 C. Sandroni, F. Cavallaro, and
- Page 665 and 666:
662 C. Sandroni, F. Cavallaro, and
- Page 667 and 668:
664 XV Neuroprotection in Sepsis by
- Page 669 and 670:
666 F. Esen XV leading to further n
- Page 671 and 672:
668 F. Esen XV can activate complem
- Page 673 and 674:
670 F. Esen XV tested the neuroprot
- Page 675 and 676:
672 F. Esen XV In sepsis, the use o
- Page 677 and 678:
674 F. Esen XV 41. Mocco J, Mack WJ
- Page 679 and 680:
676 A. Demertzi, S. Laureys, and M.
- Page 681 and 682:
678 A. Demertzi, S. Laureys, and M.
- Page 683 and 684:
680 A. Demertzi, S. Laureys, and M.
- Page 685 and 686:
682 A. Demertzi, S. Laureys, and M.
- Page 687 and 688:
Metformin and Lactic Acidosis S. Ve
- Page 689 and 690:
note, lactic acidosis may develop e
- Page 691 and 692:
unexplained lactic acidosis and hav
- Page 693 and 694:
17 ± 5 mmol/l. In one fatal case,
- Page 695 and 696:
Metformin and Lactic Acidosis 693 2
- Page 697 and 698:
Determination of Energy Goals Indir
- Page 699 and 700:
acy rates (defined as < 15 % error
- Page 701 and 702:
Energy Goals in the Critically Ill
- Page 703 and 704:
ing. Hence, while a brief period of
- Page 705 and 706:
lipogenesis, hepatic steatosis, inc
- Page 707 and 708:
educed metabolic demands of adipose
- Page 709 and 710:
Energy Goals in the Critically Ill
- Page 711 and 712:
Frailty: A New Conceptual Framework
- Page 713 and 714:
Although the concept of frailty has
- Page 715 and 716:
tion in the development of acquired
- Page 717 and 718:
digm that includes those processes
- Page 719 and 720:
Frailty: A New Conceptual Framework
- Page 721 and 722:
In the last decade, the UK reduced
- Page 723 and 724:
Access Block and Emergency Departme
- Page 725 and 726:
Potential Solutions Access Block an
- Page 727 and 728:
Access Block and Emergency Departme
- Page 729 and 730:
Triage of High-risk Surgical Patien
- Page 731 and 732:
Triage of High-risk Surgical Patien
- Page 733 and 734:
is another system calculated from s
- Page 735 and 736:
ICU Admission Guidelines Triage of
- Page 737 and 738:
Triage of High-risk Surgical Patien
- Page 739 and 740:
Triage of High-risk Surgical Patien
- Page 741 and 742:
Transportation of the Critically Il
- Page 743 and 744:
sum of several smaller - seemingly
- Page 745 and 746:
shown that intra-hospital transport
- Page 747 and 748:
is stationary, the external ventric
- Page 749 and 750:
Transportation of the Critically Il
- Page 751 and 752:
Transportation of the Critically Il
- Page 753 and 754:
Should We Still Order Chest X-rays
- Page 755 and 756:
Table 1. Item wording of the Delphi
- Page 757 and 758:
on-demand approach, such as increas
- Page 759 and 760:
Fig. 2. Assessment of intragastricp
- Page 761 and 762:
Fig. 4. Assessment of lung sliding
- Page 763 and 764:
Conclusion We have convincingly sho
- Page 765 and 766:
Should We Still Order Chest X-rays
- Page 767 and 768:
tor cells of rods (low-level light)
- Page 769 and 770:
Box 1. Examples of immune effects a
- Page 771 and 772:
The Effect of Light on Critical Ill
- Page 773 and 774:
The Effect of Light on Critical Ill
- Page 775 and 776:
Box 2. Some beneficial health effec
- Page 777 and 778:
still many nebulous aspects, and wi
- Page 779 and 780:
The Effect of Light on Critical Ill
- Page 781 and 782:
Context Information in Critical Car
- Page 783 and 784:
Fig. 2. Alternative medical problem
- Page 785 and 786:
of intensivist specialty expertise
- Page 787 and 788:
Fig. 3. XML file for context inform
- Page 789 and 790:
Context Information in Critical Car
- Page 791 and 792:
Ambient Intelligence in the Intensi
- Page 793 and 794:
cognitive networks, likely without
- Page 795 and 796:
Ambient Intelligence in the Intensi
- Page 797 and 798:
Ambient Intelligence in the Intensi
- Page 799 and 800:
Conclusion The application of rules
- Page 801 and 802:
Simulation in Critical Care Medicin
- Page 803 and 804:
Engineering a Better Simulation Exp
- Page 805 and 806:
skills development before any patie
- Page 807 and 808:
decade has to be about reaching out
- Page 809 and 810:
seriously we take the safety of our
- Page 811 and 812:
Intensive Care Medicine: Where We A
- Page 813 and 814:
direction and orientation of a prim
- Page 815 and 816:
Intensive Care Medicine: Where We A
- Page 817 and 818:
Intensive Care Medicine: Where We A
- Page 819 and 820:
Intensive Care Medicine: Where We A
- Page 821 and 822:
Subject Index Abdominal compartment
- Page 823 and 824:
C-reactive protein (CRP) 57, 268, 5
- Page 825 and 826:
Information 781 Injury severity sco
- Page 827 and 828:
Phenytoin 648 Phorbol myristate ace
- Page 829:
Vagal activity 398 - stimulation 74